Trials / Completed
CompletedNCT05896254
Study of MAR001 in Adults With Metabolic Dysfunction
A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled Study of the Safety and Efficacy of MAR001 in Patients With Metabolic Dysfunction
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 55 (actual)
- Sponsor
- Marea Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of multiple doses of MAR001in adult volunteers with metabolic dysfunction.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MAR001 | Subcutaneous injection |
| DRUG | Placebo | Subcutaneous injection |
Timeline
- Start date
- 2023-07-22
- Primary completion
- 2024-12-13
- Completion
- 2024-12-13
- First posted
- 2023-06-09
- Last updated
- 2025-11-13
Locations
2 sites across 1 country: Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05896254. Inclusion in this directory is not an endorsement.